Email updates

Keep up to date with the latest news and content from AGP and BioMed Central.

This article is part of the supplement: 1st International Congress on Neurobiology and Clinical Psychopharmacology and European Psychiatric Association Conference on Treatment Guidance

Open Access Open Badges Meeting abstract

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine

Julio Zarra1* and Luisa Schmidt2

  • * Corresponding author: Julio Zarra

Author Affiliations

1 Servicio de Psiquiatría. Hospital Italiano de La Plata. La Plata. Buenos Aires, Argentina

2 Servicio de Salud Mental. Hospital Centenario. Gualeguaychú. Entre Ríos, Argentina

For all author emails, please log on.

Annals of General Psychiatry 2010, 9(Suppl 1):S118  doi:10.1186/1744-859X-9-S1-S118

The electronic version of this article is the complete one and can be found online at:

Published:22 April 2010

© 2009 Zarra et al; licensee BioMed Central Ltd.


The efficacy, safety, and tolerability of nootropic cholinergic agent: GALANTAMINE (with a dual mechanism of action on the cholinergic a system) and moderate affinity NMDA- receptor antagonist: MEMANTINE, were assessed taking into account the profile of patients with neurocognitive disorder: Alzheimer's disease, from the clinical aspects and the different classifications.

Materials and methods

The experience included 380 patients who were enrolled in a prospective, observational, multicenter, and open-label study to receive 16 mg/day of galantamine and 30 mg/day of memantine for 12 months of treatment of addition.


The therapeutic response was measured using the Mini Mental State Examination (MMSE), Clinical Dementia Rating (CDR), Alzheimer's Disease Assessment Scale (ADAS-GOG), Functional Activities Questionnaire (FAQ) the Clinical Global Impression Scale (CGI) and the UKU scale of adverse effects taking into account the efficacy, safety and adverse events of the treatment.


The final results of the study showed that galantamine with addition memantine improves cognition, behavioural symptoms, and the general well-being of patients with cognitive impairment: Alzheimer's disease. The incidence of adverse events was not significant and a very good profile of tolerability and safety was observed.


  1. Blesa R: Galantamine: therapeutics effects beyond cognition.

    Dement Geriatr Cogn Disord 2000, 11(suppl 1):28-34. PubMed Abstract | Publisher Full Text OpenURL

  2. Sramek JJ, Veroff AE, et al.: The status of ongoing trials for mild cognitive impairment.

    Expert Opin Inveting Drugs 2001, 10(4):741-752. Publisher Full Text OpenURL